Recombinant PDCD1 (Spartalizumab Biosimilar) antibody

Catalog No. ABIN7200669

The Mouse Monoclonal anti-PDCD1 (Spartalizumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect PDCD1 (Spartalizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant PDCD1 (Spartalizumab Biosimilar) antibody (ABIN7200669)

Target: PDCD1 (Spartalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PDCD1 (Spartalizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-PDCD1 (Spartalizumab Biosimilar) Antibody

Purpose: Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody

Specificity: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Characteristics: Recombinant Humanized IgG4 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.

Isotype: IgG4 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for PDCD1 (Spartalizumab Biosimilar)

Target: PDCD1 (Spartalizumab Biosimilar)

Target Type: Biosimilar

Background: Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.